AbCellera Biologics (ABCL) Expected to Announce Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCL) is expected to release its earnings data after the market closes on Tuesday, February 18th. Analysts expect AbCellera Biologics to post earnings of ($0.15) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

AbCellera Biologics Trading Down 2.6 %

Shares of ABCL opened at $3.02 on Tuesday. The firm has a market cap of $892.02 million, a P/E ratio of -4.95 and a beta of 0.42. AbCellera Biologics has a 12 month low of $2.34 and a 12 month high of $5.46. The stock’s 50 day moving average is $3.04 and its two-hundred day moving average is $2.83.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Stifel Nicolaus reissued a “buy” rating and issued a $12.00 price target (down previously from $14.00) on shares of AbCellera Biologics in a report on Tuesday, November 5th. KeyCorp cut their target price on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Finally, Benchmark reaffirmed a “hold” rating on shares of AbCellera Biologics in a research note on Tuesday, November 5th.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.